Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, randomized, placebo-controlled, parallel-group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis

Next Previous
X
Search
Trial Profile

Double-blind, randomized, placebo-controlled, parallel-group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desloratadine (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCEPT-2
  • Sponsors Schering-Plough

    • Most Recent Events

    • 13 Jun 2019 Trial has been completed in Greece.
    • 17 Mar 2009 Results reported at AAAAI 2009.
    • 06 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top